| Name | Title | Contact Details |
|---|
Changing lives with next generation peptide therapeutics
At Vyriad, we are developing the next generation of targeted cancer therapies using engineered viruses that selectively attack cancer cells and ignite robust immune responses to prevent cancer recurrence.
RootPath, Inc. is a Cambridge, MA-based early-stage biotechnology company focusing on next-generation immuno- and cell-therapy.
Founded in 2014, Boston based Orig3n exists at the intersection of biological science and emerging technology. Through our DNA tests and community events, we help people understand the links between their genes and how their minds and bodies work. Our research team uses cutting-edge cellular science to develop personalized therapies for repairing tissue damage and disease. Together with our community, we`re on a mission to accelerate the future of regenerative medicine.
Avalanche is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. Using a next generation gene therapy platform, the Ocular BioFactory™, the Company is developing products designed to provide long-term benefit or a functional cure by inducing a sustained expression of a therapeutic protein with a one-time administration in the eye.